Jay Achar

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Hyaluronic Acid

Top Venues

Globalization and health

ERJ open research

The European respiratory journal

Journal of public health (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Stefan Kohler, Jay Achar, Christiaan Mulder, Norman Sitali, Nicolas Paul
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024. Globalization and health 20 (1) (2024)
Stefan Kohler, Jay Achar, Christiaan Mulder, Norman Sitali, Nicolas Paul
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024. Globalization and health 20 (1) (2024)
Stefan Kohler, Jay Achar, Christiaan Mulder, Norman Sitali, Nicolas Paul
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024. Globalization and health 20 (1) (2024)
Stefan Kohler, Jay Achar, Christiaan Mulder, Norman Sitali, Nicolas Paul
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024. Globalization and health 20 (1) (2024)
Jay Achar, James A Seddon, Gwenan Mary Knight, Peter J Dodd, Hanif Esmail, Jennifer Hughes, Christopher Finn McQuaid
Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing. The European respiratory journal (2023)
Stefan Kohler, Norman Sitali, Jay Achar, Nicolas Paul
Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, Uzbekistan. Journal of public health (Oxford, England) (2022)
Stefan Kohler, Norman Sitali, Jay Achar, Nicolas Paul
Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan. ERJ open research 8 (1) (2022)
Pauline Howell, Jay Achar, G Khai Lin Huang, Andrei Mariandyshev, Pawel T Schubert, Anthony J Garcia-Prats
Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities. Pathogens (Basel, Switzerland) 11 (4) (2022)
Philipp du Cros, Atadjan Khamraev, Zinaida Tigay, Tleubergen Abdrasuliev, Jane Greig, Graham Cooke, Krzysztof Herboczek, Tanya Pylypenko, Catherine Berry, Amrita Ronnachit, David Lister, Sebastian Dietrich, Cono Ariti, Khasan Safaev, Bern-Thomas Nyang'wa, Nargiza Parpieva, Mirzagalib Tillashaikhov, Jay Achar
Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan. ERJ open research 7 (1) (2021)
Syed Abidi, Jay Achar, Mourtala Mohamed Assao Neino, Didi Bang, Andrea Benedetti, Sarah Brode, Jonathon R Campbell, Esther C Casas, Francesca Conradie, Gunta Dravniece, Philipp du Cros, Dennis Falzon, Ernesto Jaramillo, Christopher Kuaban, Zhiyi Lan, Christoph Lange, Pei Zhi Li, Mavluda Makhmudova, Aung Kya Jai Maug, Dick Menzies, Giovanni Battista Migliori, Ann C Miller, Bakyt Myrzaliev, Norbert Ndjeka, Jürgen Noeske, Nargiza Parpieva, Alberto Piubello, Valérie Schwoebel, Welile Sikhondze, Rupak Singla, Mahamadou Bassirou Souleymane, Arnaud Trébucq, Armand Van Deun, Kerri Viney, Karin Weyer, Betty Jingxuan Zhang, Faiz Ahmad Khan
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. The European respiratory journal 55 (3) (2020)